1. Introduction {#sec1}
===============

Inflammatory bowel disease (IBD) may be categorized clinically as Crohn\'s disease or ulcerative colitis \[[@B1]\]. Crohn\'s disease usually causes a variety of systemic symptoms, which include chronic inflammation of the bowel \[[@B2]\]. Although any part of the digestive tract from mouth to anus may be affected, usually the small intestine (ileum) and the large intestine (colon) are involved; ileocolic Crohn\'s accounts for 50% of cases, ileal Crohn\'s for 30%, and colic Crohn\'s for 20% of cases \[[@B3]\]. Symptoms vary though its common manifestations include persistent diarrhea, rectal bleeding, abdominal cramps, and pain, though fever, extreme fatigue, and weight loss are also common \[[@B1], [@B2], [@B4]\]. Constipation is also a frequent symptom and can lead to bowel obstruction and, thus, increase the risk of bowel cancer. Complications involving other than the gastrointestinal (GI) tract include anemia, arthritis, liver disease, eye inflammation, and skin rashes \[[@B2], [@B4]\].

According to a statistical report issued by the Health Insurance Review and Assessment Service in Korea in 2016, the number of Crohn\'s disease patients increased from 13,920 in 2011 to 18,332 in 2015, an average annual increase of 7.1%. Furthermore, over the same period, total medical cost has increased by 19.4% annually, and more than half of patients are in 20s or 30s. A systematic review about the economic and quality-of-life burden of Crohn\'s disease reported that, in the USA, Germany, France, UK, Italy, and Spain, in all countries combined, Crohn\'s medical costs totaled €30 billion annually and that patient quality of life was substantially diminished by the physical, emotional, and social effects of the disease \[[@B5]\].

Although Crohn\'s disease is a global health problem \[[@B5]\], its pathology remains poorly understood \[[@B1], [@B6]\]. Nevertheless, it has been established that its etiology is associated with complex interactions between environmental, immune, microbial, and genetic factors \[[@B4], [@B7]\], though a number of authors have suggested that the primary defect in Crohn\'s disease is one of relative immunodeficiency \[[@B6], [@B8], [@B9]\].

A systematic review of publications from 1947 to 2013 involving controlled studies of herbal therapies in IBD indicated that at least 50 percent of IBD patients used some form of complementary and alternative medicine (CAM), since most herbal therapies had been reported to have anti-inflammatory effects and plausible action mechanisms in IBD with minimal adverse effects \[[@B10]\]. Moreover, herbal medicines are being increasingly used and requested by IBD patients not only in Asia, but also in Western countries \[[@B11]\].

Of the anti-inflammatory herbal medicines,*Pulsatillae Radix* (Baekduong, PR) is worth considering as a potential treatment for Crohn\'s disease as it was widely used in traditional medicine to treat amoebic dysentery and has also been demonstrated scientifically to have anti-inflammatory effects experimentally \[[@B12], [@B13]\]. PR is traditional Korean herbal medicine prepared from the roots of*Pulsatilla koreana Nakai* and contains several phytochemicals, including anemonin, hederagenin, oleanolic acid, and deoxypodophyllotoxin \[[@B14], [@B15]\]. Some experimental study results have shown that PR has various biological activities. For instance, aqueous and ethanol extracts of PR have been reported to demonstrate anticancer effects in anaplastic thyroid cancer \[[@B16]\], methanol extract of PR was found to have anti-inflammatory effects in lipopolysaccharide (LPS) exposed rats \[[@B17]\], and PR has also been reported to inhibit adipocyte differentiation and to suppress adipogenesis \[[@B13]\].

According to the meridian tropism theory of traditional medicine, the effects of PR reach to the stomach meridian and the large intestine meridian, which is in accord with the organs commonly affected by Crohn\'s disease. In terms of the selection of traditional medication, meridian tropism theory plays an important role, as it is one of the core principles of traditional medicine \[[@B18]\]. Based on meridian tropism theory, each herbal medicine possesses different affinities for certain organs and meridians of the body \[[@B19]\].

In the present study, we sought to confirm the therapeutic effects of PR in Crohn\'s disease using system level analysis and a network based in silico approach. A schematic of the network pharmacological study is summarized in [Figure 1](#fig1){ref-type="fig"}.

2. Material and Methods {#sec2}
=======================

2.1. Identification of Active Compounds {#sec2.1}
---------------------------------------

According to the Traditional Chinese Medicine Systems Pharmacology (TCMSP, <http://ibts.hkbu.edu.hk/LSP/tcmsp.php>) database (a free phytochemical database of herbal medicine), PR contains 57 identified compounds. Parameters related to absorption, distribution, metabolism, and excretion (ADME), namely, human drug-likeness (DL) \[[@B20]\], oral bioavailability (OB) \[[@B21]\], and Caco-2 permeability (Caco-2) \[[@B22]\], were employed to filter out potential active compounds.

### 2.1.1. Drug-Likeness Evaluation {#sec2.1.1}

DL helps filter out "drug-like" compounds in oriental herbs, as DL represents a qualitative concept for valuations based on how "drug-like" prospective compound is \[[@B23]\]. Accordingly, a high DL may lead to a greater possibility of therapeutic success, and compounds with a higher DL value are more likely to possess certain biological properties \[[@B24]\]. Calculations of DL in the TCMSP database are based on the Tanimoto coefficient formula \[[@B25]\] as follows:$$\begin{matrix}
{F\left( { A,B} \right) = \frac{A \times B}{A^{2} + B^{2} - A \times B},} \\
\end{matrix}$$where *A* represents the molecular parameters of herbal compounds and *B* is the average molecular parameter of all compounds in the DrugBank database (<http://www.drugbank.ca/>) \[[@B26]\]. In the present study, we excluded compounds with a DL value of \< 0.18.

### 2.1.2. Oral Bioavailability (OB) Prediction {#sec2.1.2}

Oral bioavailability (OB) is defined as the absorption ratio of an active compound into the systemic circulation, which represents convergence of the ADME process \[[@B21]\]. OB values are dependent on drug dissolution in the gastrointestinal (GI) tract, intestinal and hepatic first-pass metabolisms, and intestinal membrane permeation, and, thus, OB is considered a major pharmacokinetic parameter for drug evaluations \[[@B24]\]. In this study, the OB threshold was set as ≥ 15%.

### 2.1.3. Caco-2 Permeability Screening {#sec2.1.3}

Caco-2 permeability is used to predict the absorption of an orally administered drug \[[@B22]\]. Surface absorptivity of the small intestine is maximized by villi and microvilli; for this reason, orally administered drugs are mostly absorbed in the small intestine \[[@B27]\]. Moreover, the movement of orally administered drugs across the intestinal epithelial barrier determines the rate and extent of human absorption and ultimately affects drug bioavailability \[[@B28]\]. In the present study, compounds with OB, DL, and Caco-2 values of \>15%, \>0.18, and \>−0.4, respectively, were regarded as active and subjected to analysis. In addition, we included some compounds with lower ADME profile than above thresholds, for the reason that those were reported to possess anti-inflammatory, antioxidant, anticancer, and antibacterial effects. This study was about only one single herb, and for this reason we did not use a high threshold of ADME profile to filter potential active compounds. Instead, we lowered the standard of OB in order to analyze the most potential targets of PR.

2.2. Target Fishing {#sec2.2}
-------------------

Molecular targets of filtered potential active compounds were found in the TCMSP \[[@B29]\], Similarity Ensemble Approach (SEA, <http://sea.bkslab.org>), and the Binding Database (<http://www.bindingdb.org>). In addition, filtered compound-target interaction profile mapping was performed using the UniProt database (<http://www.uniprot.org/>) \[[@B30]\].

2.3. Gene Ontology (GO) Analysis {#sec2.3}
--------------------------------

Biological process (BP) of gene ontology (GO) analysis was employed to determine the biological properties of target genes \[[@B31]\]. GO annotation provides statistical analyses on gene function information. In this research, GO BP terms with *P* values \< 0.01 were employed and the data was collected using the DAVID 6.8 Gene Functional Classification Tool (<http://david.abcc.ncifcrf.gov/>).

2.4. Network Construction and Analysis {#sec2.4}
--------------------------------------

In order to understand the multiscale interactions between the active compounds of PR and targets, two types of networks were built: (1) a compound-target network (C-T network), in which nodes represented either compounds or target proteins, and edges indicated compound-target connections; and (2) a target-pathway network (T-P network), which was used to extract pathways from the KEGG database (<http://www.genome.jp/kegg/>) and to filter out terms highly associated with Crohn\'s disease and *P* values of \< 0.01. Related targets were mapped onto relevant pathways to produce the T-P network. Both networks were generated in Cytoscape 3.4.0, an open-source biological network visualization and data integration software package \[[@B32]\].

2.5. Target Organ Location Network {#sec2.5}
----------------------------------

Tissue-specific patterns of mRNA expression can indicate important associations with particular biological events or gene functions \[[@B33]\]. Thus, to explore the beneficial effects of PR on Crohn\'s disease, it was important to determine the tissue mRNA expression profiles of target proteins at the organ level \[[@B34]\]. The target organ location network was used with the Dataset: GeneAtlas U133A, gcrma (<http://biogps.org>). The BioGPS database provides expression data acquired by direct measurements of gene expressions by microarrays analysis \[[@B35]\]. First, the mRNA expression patterns of each target gene in 84 parts of organ tissues were obtained. Second, average values were calculated for each gene. Third, above average mRNA expressions in relevant organ tissues were extracted and arranged by frequency. Finally, a target organ location network was constructed using Cytoscape 3.4.0 and organ-specific, Crohn\'s disease related, gene overexpression data.

2.6. GEO2R Analysis {#sec2.6}
-------------------

Using Gene Expression Omnibus (GEO, <https://www.ncbi.nlm.nih.gov/geo>), we compared mRNA expression pattern of normal groups and Crohn\'s disease groups. GEOquery and limma R packages of GEO2R tool were employed to identify highly expressed genes.

2.7. Network Pathway {#sec2.7}
--------------------

In order to elucidate the action mechanisms of PR in Crohn\'s disease, filtered target proteins were input into the pathway map of inflammatory bowel disease acquired from the Kyoto Encyclopedia of Genes and Genomes (KEGG, <http://www.kegg.jp/>) database.

3. Results {#sec3}
==========

3.1. Identification of Active Compounds {#sec3.1}
---------------------------------------

Of the 57 compounds (as shown in Supplementary Table S1 in Supplementary Material available online at <https://doi.org/10.1155/2017/4198035>) in PR acquired from the TCMSP, excluding compounds with no target information, 19 compounds with a known target met the criteria OB ≥ 15%, Caco-2 ≥ −0.4, and DL ≥ 0.18. Additionally 13 compounds reported to have anti-inflammatory, antioxidant, anticancer, and antibacterial effects were added, and finally 32 compounds were analyzed (as shown in [Table 1](#tab1){ref-type="table"}).

A number of these 32 compounds have been shown experimentally to have various biological activities. For example, antioxidative effect of cernuoside (C12; DL = 0.79, OB = 2.69, Caco-2 = −1.51) was experimentally identified \[[@B36]\]. Pinoresinol (C23; DL = 0.52, OB = 4.25, Caco-2 = 0.52) was reported to have anti-inflammatory properties \[[@B37]\]. *β*-Sitosterol (C32; DL = 0.71, OB = 5.84, Caco-2 = 1.42) and campesterol (C23; DL = 0.72, OB = 5.57, Caco-2 = 1.6) were reported to have the protecting effect by natural and synthetic antioxidants during heating \[[@B38]\]. Antiallergic effects of scoparone (C25; DL = 0.09, OB = 74.75, Caco-2 = 0.85) was experimentally demonstrated in rat model, which attenuates IgE-mediated allergic response in mast cells \[[@B39]\]. Aureusidin (C7; DL = 0.24, OB = 53.42, Caco-2 = 0.07) was reported to have marked antioxidant activity and to be useful for the treatment of several diseases \[[@B40], [@B41]\], and anemosapogenin (C5; DL = 0.77, OB = 17.87, Caco-2 = 0.07) has antitumor effects \[[@B42], [@B43]\]. Betulonic acid (C9; DL = 0.78, OB = 16.83, Caco-2 = 0.65) possesses various medical effects, such as antiviral (HIV-1), anticancer, and immunomodulatory activities \[[@B44]\]. Cauloside (C11; DL = 0.4, OB = 6.84, Caco-2 = −0.82) from blue cohosh was reported to inhibit proinflammatory cytokine induction by LPS \[[@B45]\]. Dauricine (C13; DL = 0.9, OB = 23.65, Caco-2 = 0.37) from Asiatic moonseed was reported to have significant antibacterial and anti-inflammatory effects \[[@B46]\], and ergosterol (C14; DL = 0.72, OB = 14.29, Caco-2 = 1.47) \[[@B47]\] from the mushroom and isorhamnetin (C17; DL = 0.31, OB = 49.6, Caco-2 = 0.31) \[[@B48]\] were both found to have anti-inflammatory effects. Furthermore, oleanolic acid (C21; DL = 0.76, OB = 29.02, Caco-2 = 0.59) and ursolic acids (C30; DL = 0.75, OB = 16.77, Caco-2 = 0.67) have been reported to have antioxidative and anti‐inflammatory effect \[[@B49], [@B50]\]. As mentioned above, PR contains many compounds, which are ubiquitous in plants, herbs, and fruits, with anti-inflammatory, anticancer, and antioxidative effects.

3.2. Target Fishing {#sec3.2}
-------------------

These 32 identified active compounds interact with 182 target proteins ([Table 2](#tab2){ref-type="table"}); that is, on average, they interact with 5.7 target genes, which does much to explain the polypharmacological and synergistic effects of PR on multiple targets \[[@B51]\].

3.3. GO Analysis {#sec3.3}
----------------

For the filtered 182 target genes, 469 biological process terms with *P* values of \< 0.01 were sorted using the functional annotation chart of the DAVID 6.8 Gene Functional Classification Tool and *P* values were adjusted using Benjamini-Hochberg method. This process resulted in the identification of 25 biological process terms. GO analysis showed that the 182 genes were highly related to inflammation, proliferation, oxidation reduction, and the regulations of apoptosis and signal transduction ([Figure 2](#fig2){ref-type="fig"}).

In detail, phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit, gamma isoform (PIK3CG), interleukin-6 (IL6), tumor necrosis factor (TNF), C-C motif chemokine 2 (CCL2), prostaglandin E2 receptor EP3 subtype (PTGER3), oxidized low-density lipoprotein receptor 1 (OLR1), prostaglandin G/H synthase 2 (PTGS2), and others are related to "inflammatory response."

Androgen receptor (AR), interleukin-6 (IL6), heparin-binding growth factor 2 (FGF2), GTPase HRas (HRAS), hematopoietic cell protein-tyrosine phosphatase (PTPN6), and signal transducer and activator of transcription 3 (STAT3) are related to both the "positive regulation and negative regulation of cell proliferation."

Xanthine dehydrogenase/oxidase (XDH), 5,6-dihydroxyindole-2-carboxylic acid oxidase (TYRP1), prostaglandin G/H synthase 2 (PTGS2), neutrophil cytosol factor 1 (NCF1), lanosterol 14-alpha demethylase (CYP51A1), amine oxidase \[flavin-containing\] A (MAOA), dual oxidase 2 (DUOX2), and others are associated with "oxidation-reduction process."

Bcl-2-like protein 1 (BCL2L1), interleukin-6 (IL6), mitogen-activated protein kinase 8 (MAPK8), and cellular tumor antigen p53 (TP53) are associated with both the "positive regulation and negative regulation of apoptotic process."

To summarize, it is likely that the therapeutic effect of PR in Crohn\'s disease is due to its anti-inflammatory and repair process and immune system enhancing effects.

3.4. Network Construction and Analysis {#sec3.4}
--------------------------------------

To visualize more conveniently the multitargeted effects of PR, network analysis was used to investigate its actions within the context of the whole human genome \[[@B52], [@B53]\]. As shown in [Figure 3](#fig3){ref-type="fig"}, constructed (A) C-T and (B) T-P network demonstrated multicompound and multitargeted effects and relations between various pathways and targets. Circular nodes represent compounds and targets in the C-T network and triangles and circular nodes show pathways and compounds in the T-P network. In both networks, node size was regulated by degree centrality and edges showed interactions between nodes.

The C-T network showed 415 interactions between the 182 targets and 32 active compounds of PR. Ursolic acid (C30, degree = 55) had the highest number of interactions with targets, followed by beta-sitosterol (C8, degree = 37) and isorhamnetin (C17, degree = 36), and, thus, these results demonstrated that single molecules can target multiple receptors \[[@B54]\]. Likewise, prostaglandin G/H synthase 2 (PTGS2, degree = 15) displayed the most affinitive connections with compounds, followed by prostaglandin G/H synthase 1 (PTGS1, degree = 13) and nuclear receptor coactivator 2 (NCOA2, degree = 11). According to betweenness centrality results, protein-tyrosine phosphatase 1B (PTPN1, betweenness = 0.11) was second highest followed by PTGS2 (betweenness = 0.12). 28 (88%) Of the 32 active compounds were connected with more than two targets and 86 (47%) of the 182 targets interact with more than one compound. This network analysis results clearly demonstrated the multitargeting natures of herbal compounds; besides it showed that ursolic acid (C30) is the most essential compound in PR.

In addition, 40 pathways related to Crohn\'s disease were extracted to construct the T-P network. According to degree centrality, "pathways in cancer" (degree = 49) had the highest number of connections with the targets, followed by the "PI3K-Akt signaling pathway" (degree = 34) and "hepatitis B" (degree = 33). In the same manner, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA, degree = 33), phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PIK3CG, degree = 33), and nuclear factor NF-*κ*B p65 subunit (RELA, degree = 25) demonstrate higher affinitive connections with pathways. Betweenness centrality and degree centrality results were similar; there was only little difference. "Pathways in cancer" (betweenness = 0.19) had the highest betweenness among the targets, which concurred with degree centrality, and this was followed by "neuroactive ligand-receptor interaction" (betweenness = 0.15) and "PI3K-Akt signaling pathway" (betweenness = 0.10). Regarding highest betweenness targets, PIK3CA (betweenness = 0.10), PIK3CG (betweenness = 0.10), and prostaglandin E2 receptor EP3 subtype (PTGER3, betweenness = 0.04) showed most affinitive connections with pathways.

3.5. Target Organ Location Network {#sec3.5}
----------------------------------

The tissue mRNA expression profiles of target genes at the organ level were investigated to identify effects of PR on Crohn\'s disease. No mRNA expression information of three of genes, muscarinic acetylcholine receptor M1 (CHRM1), G-protein coupled receptor TGR-1 (NMUR2), and taste receptor type 2 member 31 (TAS2R31), was found in the BioGPS. In total, the mRNA expression profiles of 179 of 182 genes were analyzed (Supplementary Table S2). 158 Of the genes displayed above average mRNA expressions in 17 relevant organ tissues, namely, in BDCA4+ dendritic cells, bone marrow, CD14+ monocytes, CD19+ B cells, CD33+ myeloid cells, CD34+ hematopoietic stem cells, CD4+ T cells, CD56+ NK cells, CD8+ T cells, colon, colorectal adenocarcinoma, liver, lymph nodes, lymphoblasts, small intestine, smooth muscle, and thymus. In addition, these 17 organ tissues, retina, prefrontal cortex, pineal, amygdala, cardiac myocyte, heart, whole blood, and other tissues, were also associated with relatively high mRNA expressions. Networks of the tissue mRNA expressions of 158 target genes and PR compounds are shown in [Figure 4](#fig4){ref-type="fig"}, nodes represent organs and genes, and node sizes indicate the number of interactions between nodes.

In detail, among 84 organ tissues, CD33+ myeloid showed the most overexpressed mRNA expression, 104 genes of 158 target genes were overexpressed in CD33+ myeloid, followed by 97 genes in lymphoblasts, 95 in each of smooth muscle and CD34+ hematopoietic stem cells, 91 genes in liver and CD56+ NK cell, 84 in bone marrow and colorectal adenocarcinoma, 82 in BDCA4+ dendritic cells, 75 in CD14+ monocytes, 73 in small intestine, 72 in CD4+ T cells, 70 in CD19+ B cells, 67 in colon, 38 in CD8+ T cells, 23 in thymus, and 22 in lymph nodes. It is evident that most genes were overexpressed in several organs at the same time.

Additionally, intestinal alkaline sphingomyelinase (ENPP7), DNA polymerase catalytic subunit (POLG), and carbonic anhydrase 13 (CA13) recorded beyond average mRNA expressions in all 17 organs. Furthermore, more than 146 (92%) of 158 target genes were overexpressed in two or more organ tissues, suggesting that these organs and compounds in PR are closely related. Furthermore, because the above 17 organs are highly related to immunity, our study results indicate that the therapeutic effects of PR on Crohn\'s disease are due to its targeting and activating the immune system.

The other 21 target genes, such as acetylcholinesterase (ACHE), pancreatic alpha-amylase (AMY2A), and muscarinic acetylcholine receptor M3 (CHRM3), did not show above average mRNA expression in the 17 organs.

3.6. GEO2R Analysis {#sec3.6}
-------------------

Comparison data between normal tissue and Crohn\'s disease patients\' mRNA expression pattern from Gene Expression Omnibus (GEO) was collected. We employed GEOquery and limma R packages of GEO2R tool to identify highly expressed genes in 6 datasets. Dataset accession numbers are as follows: GSE24287, GSE60083, GSE6731, GSE36807, GSE68570, and GSE72780. To sum up, 86 normal samples and 149 Crohn\'s disease samples were analyzed in each dataset. GEO2R presented the top 250 highly expressed genes in Crohn\'s disease group compared to the control group and we deleted overlaps, so, in the end, 1182 genes were sorted out.

We found out that there were 23 common genes ([Table 3](#tab3){ref-type="table"}) between target genes of PR and highly expressed genes of Crohn\'s disease dataset from GEO.

3.7. Network Pathway {#sec3.7}
--------------------

In order to investigate further the effect of PR in Crohn\'s disease, we performed pathway enrichment analysis ([Figure 5](#fig5){ref-type="fig"}). Using the IBD pathway provided by the KEGG pathway database, we confirmed the pathway mapping effect of PR in Crohn\'s disease by inputting the filtered human target genes into the pathway. The KEGG pathway was constructed according to the current knowledge of the pathogenesis IBD.

The synthesis of inflammatory cytokines, such as IL-1, IL-6 and TNF-*α*, is mediated by NF-*κ*B, which is a key regulator of inflammation \[[@B55], [@B56]\]. We found that oleanolic acid derivative (C22) targets IL-1; ursolic acid (C30) targets all of IL-1, IL-6, and TNF; isorhamnetin (C17), scoparone (C25), and ursolic acid (C30) target nuclear factor NF-*κ*B p65 subunit (RELA); and scoparone (C25) and ursolic acid (C30) target NF-*κ*B inhibitor alpha (CHUK), which suggests that these compounds affect NF-*κ*B activity. Cernuoside (C12) targets IL-2. Beta-sitosterol (C8) targets transforming growth factor beta-1 (TGFB1) and transcription factor AP-1 (JUN), and ursolic acid (C30) also targets transcription factor AP-1 (JUN) and signal transducer and activator of transcription 3 (STAT3). Furthermore, NF-*κ*B and AP-1 in combination are highly related to the initial inflammatory response and to the development of acquired immunity \[[@B57]\]. Moreover, IL-6-mediated STAT3 activation on mucosal T cells may has been suggested to play a role in the development of IBD \[[@B58]\].

4. Discussion {#sec4}
=============

In this study, a network pharmacology method with active compounds filtration, multiple drug target prediction, gene ontology, network analysis, relevant organ location network, and pathway enrichment analysis were employed to determine the targets of PR in relation to Crohn\'s disease. Our study shows that PR is highly connected to the pathways, biological processes, and organs of Crohn\'s disease. A pharmacological approach was used to identify the actions of PR at the systems network level.

In this study, pathway mapping result showed that the target genes of PR overlap more with Crohn\'s disease than with ulcerative colitis. Experimental study also suggested that the markers of both diseases are different from each other \[[@B59], [@B60]\]. The clinical symptoms of these diseases also differ; for instance, Crohn\'s disease affect any region of the entire gastrointestinal (GI) tract and all layers of the bowel wall, whereas ulcerative colitis affects only the mucosa and submucosa of colon \[[@B61]\]. Furthermore, ulcerative colitis can be cured by surgery, but Crohn\'s disease of any part of GI tract tends to relapse after surgery \[[@B62]\]. For this reason, long term management using herbal medicines might be highly recommendable treatment option for Crohn\'s disease, since herbal medicines have advantages for managing chronic diseases \[[@B63], [@B64]\].

In addition, IBD is usually referred to as an autoimmune disorder \[[@B65]\], whereas Crohn\'s disease does not meet the criteria of an autoimmune disorder; rather it is associated with immune deficiency or a secondary immune response to altered intestinal microbiota \[[@B65]\]. Furthermore, ulcerative colitis is a mucosal disease where autoimmune autoantibodies are commonly detected \[[@B67]\], whereas Crohn\'s disease is a transmural disease, in which pathological changes in gut wall are thought to result from submucosal inflammatory changes \[[@B68]\]. Accordingly, the areas targeted for treatment in these two diseases should be differentiated.

In the present study, we focused on the use of PR as a potential therapy for Crohn\'s disease. However, herb pairs and combinations are more commonly prescribed and are regarded to be more effective and safer \[[@B69]\]. In terms of the Gunsinjwasa theory of traditional medicine combinations, there are four different roles for each herb in the formula. First, the major component targets the main symptom. Second, the supportive component assists the effect of the major component or targets the secondary symptoms. Third, the neutralizing component allays the side effects or toxins of the major and the supportive component. Fourth, the deliver/retaining component guides the medicine to the targeting part of the body \[[@B70], [@B71]\]. This combination principle enables not only the enhancement of synergistic medicinal effects but also potentially reduces toxicities \[[@B70]\]. In order to induce better effects and reduce toxicities, an extended analysis of the*Pulsatillae Radix* (Baekduong, PR),*Phellodendri Cortex* (Hwangbaek),*Coptidis Rhizoma* (Hwangryeon), and*Citrus reticulata* (Jinpi) herb combination (a widely prescribed formula, known as Baekduong decoction) should be explored in the future.

Through GO analysis, we found out that targets of PR are associated with liver diseases such as hepatitis B, hepatitis C, and nonalcoholic fatty liver. In addition, the mRNA expression of 91 of 179 genes in liver was overexpressed according to the target organ location network result. Liver inflammation is as common extraintestinal symptom of Crohn\'s disease \[[@B72]\], and the number of liver abscesses in Crohn\'s disease patients is 15 to 20 times higher than that found in the general population \[[@B73]\]. Besides biochemical liver dysfunction \[[@B74]\] and hepatic fibrosis \[[@B75]\] are also frequently found in Crohn\'s disease, and a number of drugs used to treat IBD have been reported to be associated with liver injury \[[@B76]\]. Furthermore, in an experimental study using a mice model of Crohn\'s disease-like ileitis, it was found that TLR9 plays an important role in hepatic involvement in IBD \[[@B72]\]. More detailed pathways and relations between liver and Crohn\'s disease should be discussed in the future.

This study demonstrated that 73 and 67 of 158 targets of PR were highly expressed in small intestine and colon, respectively, results which were accordance with not only the organs commonly affected by Crohn\'s disease but also the properties of PR in terms of meridian tropism theory. However stronger evidence with another research design is required to support this result.

We confirmed a multicompound and multitarget interaction through the C-T network, which showed that 88% of the active compounds were connected with more than two targets and 47% of the targets interacted with more than one compound. Although it demonstrated the synergetic network of multitarget actions, we should explore more differentiated drug action based on degree centrality and how different the drug actions are when more compounds target one gene in simultaneous way compared to the case of one compound targeting one gene.

5. Conclusion {#sec5}
=============

Previous studies indicate that most compounds in PR have anti-inflammatory, anticancer, and antioxidant effects. In the present study, we found that these compounds interact with multiple targets in a synergetic manner and that PR is highly connected to Crohn\'s disease related pathways, biological processes, and organs. C-T and T-P network results demonstrated complex multicompound and multitarget drug actions and the relations between targets and various pathways. Furthermore, target genes were found to be overexpressed in organs highly related to immunity. These findings suggest the anti-inflammatory effects of PR, and its enhancements of repair processes and immune system might be of therapeutic benefit in Crohn\'s disease.

Supplementary Material {#supplementary-material-sec}
======================

###### 

Supplementary Table S1 showed the ADME profiles of 57 compounds in PR, and supplementary Table S2 demonstrated the mRNA expression profiles of 179 of 182 genes.
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![Workflow: network analysis, relevant organ location network analysis, gene ontology, and pathway analysis were performed on active compounds identified in*Pulsatillae Radix* (PR) by screening and target fishing.](ECAM2017-4198035.001){#fig1}

![GO analysis: 25 biological process (BP) of gene ontology (GO) terms sorted by *P* value \< 0.01. Counts of genes and *P* value related to each BP terms are shown. The *y*-axis represents BP terms for the target genes, and the *x*-axis shows counts of genes and −log⁡~10~(*P* value).](ECAM2017-4198035.002){#fig2}

![C-T network and T-P network: (a) is a compound-target (C-T) network, and nodes represent compounds and targets; and (b) shows a target-pathway (T-P) network, and circular nodes represent compounds and triangles pathways. Node size is related to the degree and edges demonstrate interactions between nodes.](ECAM2017-4198035.003){#fig3}

![Target organ location network: the tissue-specific patterns of the mRNA expressions of targets in organs related to the immune system, colon, and small intestine. Nodes represent targets and organ locations. Node size is relative to the degree. Gene expression data was based on gene expression microarrays analysis results in BioGPS.](ECAM2017-4198035.004){#fig4}

![Network pathway: pathway enrichment analysis was performed. 182 filtered target genes were mapped into the Crohn\'s disease pathway from the Kyoto Encyclopedia of Genes and Genomes (KEGG) to confirm the possible effect pathway of*Pulsatillae Radix* (PR) on Crohn\'s disease.](ECAM2017-4198035.005){#fig5}

###### 

32 potential active compounds of *Pulsatillae Radix*.

  ID    Active compounds           Structure                             OB (%)   Caco-2   DL
  ----- -------------------------- ------------------------------------- -------- -------- -------
  C1    3-Methylcoumarin           ![](ECAM2017-4198035.tab1.i001.jpg)   19.66    1.27     0.05
                                                                                           
  C2    5,6,7-Trimethoxycoumarin   ![](ECAM2017-4198035.tab1.i002.jpg)   32.54    0.94     0.12
                                                                                           
  C3    AIDS045703                 ![](ECAM2017-4198035.tab1.i003.jpg)   21.37    0.55     0.87
                                                                                           
  C4    Androstane-3,11,17-triol   ![](ECAM2017-4198035.tab1.i004.jpg)   13.19    −0.04    0.38
                                                                                           
  C5    Anemosapogenin             ![](ECAM2017-4198035.tab1.i005.jpg)   17.87    0.07     0.77
                                                                                           
  C6    Anemoside A3               ![](ECAM2017-4198035.tab1.i006.jpg)   15.46    −1.6     0.15
                                                                                           
  C7    Aureusidin                 ![](ECAM2017-4198035.tab1.i007.jpg)   53.42    0.07     0.24
                                                                                           
  C8    Beta-sitosterol            ![](ECAM2017-4198035.tab1.i008.jpg)   36.91    1.32     0.75
                                                                                           
  C9    Betulonic acid             ![](ECAM2017-4198035.tab1.i009.jpg)   16.83    0.65     0.78
                                                                                           
  C10   Campesterol                ![](ECAM2017-4198035.tab1.i010.jpg)   5.57     1.6      0.72
                                                                                           
  C11   Cauloside A                ![](ECAM2017-4198035.tab1.i011.jpg)   6.84     −0.82    0.4
                                                                                           
  C12   Cernuoside                 ![](ECAM2017-4198035.tab1.i012.jpg)   2.69     −1.51    −2.18
                                                                                           
  C13   Dauricine (8CI)            ![](ECAM2017-4198035.tab1.i013.jpg)   23.65    0.9      0.37
                                                                                           
  C14   Ergosterol                 ![](ECAM2017-4198035.tab1.i014.jpg)   14.29    1.47     0.72
                                                                                           
  C15   Fraxinol                   ![](ECAM2017-4198035.tab1.i015.jpg)   24.19    0.7      0.1
                                                                                           
  C16   Hederagenol                ![](ECAM2017-4198035.tab1.i016.jpg)   22.42    0.1      0.74
                                                                                           
  C17   Isorhamnetin               ![](ECAM2017-4198035.tab1.i017.jpg)   49.6     0.31     0.31
                                                                                           
  C18   LAN                        ![](ECAM2017-4198035.tab1.i018.jpg)   42.12    1.52     0.75
                                                                                           
  C19   Lignoceric acid            ![](ECAM2017-4198035.tab1.i019.jpg)   14.9     1.24     0.33
                                                                                           
  C20   Mairin                     ![](ECAM2017-4198035.tab1.i020.jpg)   55.38    0.73     0.78
                                                                                           
  C21   Oleanolic acid             ![](ECAM2017-4198035.tab1.i021.jpg)   29.02    0.59     0.76
                                                                                           
  C22   Oleanolic acid deriv.      ![](ECAM2017-4198035.tab1.i022.jpg)   14.24    0.65     0.7
                                                                                           
  C23   Pinoresinol                ![](ECAM2017-4198035.tab1.i023.jpg)   4.25     0.52     0.52
                                                                                           
  C24   Pulchinenoside A_qt        ![](ECAM2017-4198035.tab1.i024.jpg)   16.91    0.12     0.77
                                                                                           
  C25   Scoparone                  ![](ECAM2017-4198035.tab1.i025.jpg)   74.75    0.85     0.09
                                                                                           
  C26   Sitogluside                ![](ECAM2017-4198035.tab1.i026.jpg)   20.63    −0.14    0.62
                                                                                           
  C27   Sitosteryl acetate         ![](ECAM2017-4198035.tab1.i027.jpg)   40.39    1.39     0.85
                                                                                           
  C28   Stigmasterol               ![](ECAM2017-4198035.tab1.i028.jpg)   43.83    1.44     0.76
                                                                                           
  C29   Tricosanoic acid           ![](ECAM2017-4198035.tab1.i029.jpg)   15.29    1.18     0.3
                                                                                           
  C30   Ursolic acid               ![](ECAM2017-4198035.tab1.i030.jpg)   16.77    0.67     0.75
                                                                                           
  C31   ZINC01615307               ![](ECAM2017-4198035.tab1.i031.jpg)   56.38    0.53     0.87
                                                                                           
  C32   *β*-Sitosterol             ![](ECAM2017-4198035.tab1.i032.jpg)   5.84     1.42     0.71

###### 

Related targets of *Pulsatillae Radix*.

  UniProt ID   Target                                                                            Gene name
  ------------ --------------------------------------------------------------------------------- -----------
  Q92887       Canalicular multispecific organic anion transporter 1                             ABCC2
  P12821       Angiotensin-converting enzyme                                                     ACE
  P22303       Acetylcholinesterase                                                              ACHE
  P24666       Low molecular weight phosphotyrosine protein phosphatase                          ACP1
  P00326       Alcohol dehydrogenase 1C                                                          ADH1C
  P35348       Alpha-1A adrenergic receptor                                                      ADRA1A
  P35368       Alpha-1B adrenergic receptor                                                      ADRA1B
  P25100       Alpha-1D adrenergic receptor                                                      ADRA1D
  P08913       Alpha-2A adrenergic receptor                                                      ADRA2A
  P18825       Alpha-2C adrenergic receptor                                                      ADRA2C
  P08588       Beta-1 adrenergic receptor                                                        ADRB1
  P07550       Beta-2 adrenergic receptor                                                        ADRB2
  P15121       Aldose reductase                                                                  AKR1B1
  O60218       Aldo-keto reductase family 1 member B10                                           AKR1B10
  P09917       Arachidonate 5-lipoxygenase                                                       ALOX5
  P09923       Intestinal-type alkaline phosphatase                                              ALPI
  P04746       Pancreatic alpha-amylase                                                          AMY2A
  P10275       Androgen receptor                                                                 AR
  P15336       Cyclic AMP-dependent transcription factor ATF-2                                   ATF2
  P05023       Sodium/potassium-transporting ATPase subunit alpha-1                              ATP1A1
  P15291       Beta-1,4-galactosyltransferase 1                                                  B4GALT1
  Q07812       Apoptosis regulator BAX                                                           BAX
  P10415       Apoptosis regulator Bcl-2                                                         BCL2
  Q07817       Bcl-2-like protein 1                                                              BCL2L1
  O15392       Baculoviral IAP repeat-containing protein 5                                       BIRC5
  O43570       Carbonic anhydrase 12                                                             CA12
  Q8N1Q1       Carbonic anhydrase 13                                                             CA13
  P00918       Carbonic anhydrase II                                                             CA2
  P22748       Carbonic anhydrase IV                                                             CA4
  P35218       Carbonic anhydrase 5A, mitochondrial                                              CA5A
  Q16790       Carbonic anhydrase VI                                                             CA9
  P62158       Calmodulin                                                                        CALM1
  P29466       Caspase-1                                                                         CASP1
  P42574       Caspase-3                                                                         CASP3
  Q14790       Caspase-8                                                                         CASP8
  P55211       Caspase-9                                                                         CASP9
  P13500       C-C motif chemokine 2                                                             CCL2
  P20248       Cyclin-A2                                                                         CCNA2
  P24385       G1/S-specific cyclin-D1                                                           CCND1
  P30279       G1/S-specific cyclin-D2                                                           CCND2
  P60033       CD81 antigen                                                                      CD81
  P24941       Cell division protein kinase 2                                                    CDK2
  P11802       Cell division protein kinase 4                                                    CDK4
  Q00534       Cell division protein kinase 6                                                    CDK6
  P38936       Cyclin-dependent kinase inhibitor 1                                               CDKN1A
  O14757       Serine/threonine-protein kinase Chk1                                              CHEK1
  P11229       Muscarinic acetylcholine receptor M1                                              CHRM1
  P08172       Muscarinic acetylcholine receptor M2                                              CHRM2
  P20309       Muscarinic acetylcholine receptor M3                                              CHRM3
  P08173       Muscarinic acetylcholine receptor M4                                              CHRM4
  Q15822       Neuronal acetylcholine receptor subunit alpha-2                                   CHRNA2
  P36544       Neuronal acetylcholine receptor protein, alpha-7 chain                            CHRNA7
  O15111       NF-kappa-B inhibitor alpha                                                        CHUK
  P16220       Cyclic AMP-responsive element-binding protein 1                                   CREB1
  P15509       Granulocyte-macrophage colony-stimulating factor                                  CSF2RA
  P17538       Chymotrypsinogen B                                                                CTRB1
  P07858       Cathepsin B                                                                       CTSB
  P10145       Interleukin-8                                                                     CXCL8
  Q16850       Lanosterol 14-alpha demethylase                                                   CYP51A1
  Q9UBM7       7-Dehydrocholesterol reductase                                                    DHCR7
  P27487       Dipeptidyl peptidase IV                                                           DPP4
  P21728       Dopamine D1 receptor                                                              DRD1
  Q9NRD8       Dual oxidase 2                                                                    DUOX2
  Q6UWV6       Intestinal alkaline sphingomyelinase                                              ENPP7
  Q99814       Endothelial PAS domain-containing protein 1                                       EPAS1
  P03372       Estrogen receptor                                                                 ESR1
  Q92731       Estrogen receptor beta                                                            ESR2
  P00742       Coagulation factor Xa                                                             F10
  P00734       Thrombin                                                                          F2
  P08709       Coagulation factor VII                                                            F7
  P48023       Tumor necrosis factor ligand superfamily member 6                                 FASLG
  P49327       Fatty acid synthase                                                               FASN
  P05230       Fibroblast growth factor 1                                                        FGF1
  P09038       Heparin-binding growth factor 2                                                   FGF2
  P01100       Proto-oncogene c-Fos                                                              FOS
  P14867       Gamma-aminobutyric acid receptor subunit alpha-1                                  GABRA1
  P47869       Gamma-aminobutyric-acid receptor alpha-2 subunit                                  GABRA2
  P34903       Gamma-aminobutyric-acid receptor alpha-3 subunit                                  GABRA3
  P31644       Gamma-aminobutyric-acid receptor alpha-5 subunit                                  GABRA5
  P17677       Neuromodulin                                                                      GAP43
  Q8TDU6       G-protein coupled bile acid receptor 1                                            GPBAR1
  P42262       Glutamate receptor 2                                                              GRIA2
  P49841       Glycogen synthase kinase-3 beta                                                   GSK3B
  Q9UII4       Probable E3 ubiquitin-protein ligase HERC5                                        HERC5
  P09601       Heme oxygenase 1                                                                  HMOX1
  P01112       GTPase HRas                                                                       HRAS
  P28845       Corticosteroid 11-beta-dehydrogenase isozyme 1                                    HSD11B1
  P80365       Corticosteroid 11-beta-dehydrogenase isozyme 2                                    HSD11B2
  P08238       Heat shock protein HSP 90                                                         HSP90AB1
  P28223       5-Hydroxytryptamine 2A receptor                                                   HTR2A
  P46098       5-Hydroxytryptamine receptor 3A                                                   HTR3A
  P05362       Intercellular adhesion molecule 1                                                 ICAM1
  P01857       Ig gamma-1 chain C region                                                         IGHG1
  P01584       Interleukin-1 beta                                                                IL1B
  P60568       Interleukin-2                                                                     IL2
  P05231       Interleukin-6                                                                     IL6
  O15357       Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 2                          INPPL1
  P05412       Transcription factor AP-1                                                         JUN
  Q12809       Potassium voltage-gated channel subfamily H member 2                              KCNH2
  Q12791       Calcium-activated potassium channel subunit alpha 1                               KCNMA1
  O75164       Lysine-specific demethylase 4A                                                    KDM4A
  P35968       Vascular endothelial growth factor receptor 2                                     KDR
  Q99732       Lipopolysaccharide-induced tumor necrosis factor-alpha factor                     LITAF
  P09960       Leukotriene A-4 hydrolase                                                         LTA4H
  P21397       Amine oxidase \[flavin-containing\] A                                             MAOA
  P27338       Amine oxidase \[flavin-containing\] B                                             MAOB
  P11137       Microtubule-associated protein 2                                                  MAP2
  Q16539       Mitogen-activated protein kinase 14                                               MAPK14
  P45983       Mitogen-activated protein kinase 8                                                MAPK8
  Q13387       C-Jun-amino-terminal kinase-interacting protein 2                                 MAPK8IP2
  Q07820       Induced myeloid leukemia cell differentiation protein Mcl-1                       MCL1
  P14174       L-Dopachrome tautomerase                                                          MIF
  P03956       Interstitial collagenase                                                          MMP1
  P09238       Stromelysin-2                                                                     MMP10
  P08253       72 kDa type IV collagenase                                                        MMP2
  P08254       Stromelysin-1                                                                     MMP3
  P14780       Matrix metalloproteinase-9                                                        MMP9
  P42345       Serine/threonine-protein kinase mTOR                                              MTOR
  P14598       Neutrophil cytosol factor 1                                                       NCF1
  Q15788       Nuclear receptor coactivator 1                                                    NCOA1
  Q15596       Nuclear receptor coactivator 2                                                    NCOA2
  Q9GZQ4       Neuromedin-U receptor 2                                                           NMUR2
  P35228       Nitric oxide synthase, inducible                                                  NOS2
  P29474       Nitric oxide synthase, endothelial                                                NOS3
  P15559       NAD(P)H dehydrogenase \[quinone\] 1                                               NQO1
  P04150       Glucocorticoid receptor                                                           NR3C1
  P08235       Mineralocorticoid receptor                                                        NR3C2
  P01111       GTPase NRas                                                                       NRAS
  P78380       Oxidized low-density lipoprotein receptor 1                                       OLR1
  P35372       Mu-type opioid receptor                                                           OPRM1
  P07237       Protein disulfide-isomerase                                                       P4HB
  Q14432       CGMP-inhibited 3′,5′-cyclic phosphodiesterase A                                   PDE3A
  P16284       Platelet endothelial cell adhesion molecule                                       PECAM1
  P06401       Progesterone receptor                                                             PGR
  P42336       Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform    PIK3CA
  P48736       Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform   PIK3CG
  P11309       Proto-oncogene serine/threonine-protein kinase Pim-1                              PIM1
  P61925       cAMP-dependent protein kinase inhibitor alpha                                     PKIA
  P00749       Urokinase-type plasminogen activator                                              PLAU
  P19174       1-Phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1                 PLCG1
  P09884       DNA polymerase alpha catalytic subunit                                            POLA1
  P06746       DNA polymerase beta                                                               POLB
  P54098       DNA polymerase catalytic subunit                                                  POLG
  P27169       Serum paraoxonase/arylesterase 1                                                  PON1
  Q03181       Peroxisome proliferator activated receptor delta                                  PPARD
  P37231       Peroxisome proliferator activated receptor gamma                                  PPARG
  P17612       mRNA of PKA catalytic subunit C-alpha                                             PRKACA
  P17252       Protein kinase C alpha type                                                       PRKCA
  P05129       Protein kinase C gamma type                                                       PRKCG
  P07477       Trypsin-1                                                                         PRSS1
  P43115       Prostaglandin E2 receptor EP3 subtype                                             PTGER3
  O14684       Prostaglandin E synthase                                                          PTGES
  P23219       Prostaglandin G/H synthase 1                                                      PTGS1
  P35354       Prostaglandin G/H synthase 2                                                      PTGS2
  P18031       Protein-tyrosine phosphatase 1B                                                   PTPN1
  P17706       T-cell protein-tyrosine phosphatase                                               PTPN2
  P29350       Hematopoietic cell protein-tyrosine phosphatase                                   PTPN6
  P11217       Glycogen phosphorylase, muscle form                                               PYGM
  Q04206       Transcription factor p65                                                          RELA
  P19793       Retinoic acid receptor RXR-alpha                                                  RXRA
  Q14524       Sodium channel protein type 5 subunit alpha                                       SCN5A
  P16581       E-selectin                                                                        SELE
  Q9HAS3       Solute carrier family 28 member 3                                                 SLC28A3
  O43826       Glucose-6-phosphate translocase                                                   SLC37A4
  P13866       Sodium/glucose cotransporter 1                                                    SLC5A1
  P31639       Sodium/glucose cotransporter 2                                                    SLC5A2
  Q9NY91       Low affinity sodium-glucose cotransporter                                         SLC5A4
  P23975       Sodium-dependent noradrenaline transporter                                        SLC6A2
  Q01959       Sodium-dependent dopamine transporter                                             SLC6A3
  P31645       Sodium-dependent serotonin transporter                                            SLC6A4
  Q9Y6L6       Solute carrier organic anion transporter family member 1B1                        SLCO1B1
  P40763       Signal transducer and activator of transcription 3                                STAT3
  P59538       Taste receptor type 2 member 31                                                   TAS2R31
  P01137       Transforming growth factor beta-1                                                 TGFB1
  P01375       Tumor necrosis factor                                                             TNF
  P11388       DNA topoisomerase II alpha                                                        TOP2A
  P04637       Cellular tumor antigen p53                                                        TP53
  P17752       Tryptophan 5-hydroxylase 1                                                        TPH1
  P14679       Tyrosinase                                                                        TYR
  P17643       5,6-dihydroxyindole-2-carboxylic acid oxidase                                     TYRP1
  P15692       Vascular endothelial growth factor A                                              VEGFA
  P47989       Xanthine dehydrogenase/oxidase                                                    XDH

###### 

Highly expressed targets in Crohn\'s disease.

  UniProt ID   Target                                                  Gene name
  ------------ ------------------------------------------------------- -----------
  Q92887       Canalicular multispecific organic anion transporter 1   ABCC2
  O60218       Aldo-keto reductase family 1 member B10                 AKR1B10
  P09917       Arachidonate 5-lipoxygenase                             ALOX5
  P62158       Calmodulin                                              CALM1
  Q00534       Cell division protein kinase 6                          CDK6
  P10145       Interleukin-8                                           CXCL8
  Q99814       Endothelial PAS domain-containing protein 1             EPAS1
  P01100       Proto-oncogene c-Fos                                    FOS
  P47869       Gamma-aminobutyric-acid receptor alpha-2 subunit        GABRA2
  P49841       Glycogen synthase kinase-3 beta                         GSK3B
  P09601       Heme oxygenase 1                                        HMOX1
  P05362       Intercellular adhesion molecule 1                       ICAM1
  P01584       Interleukin-1 beta                                      IL1B
  P05231       Interleukin-6                                           IL6
  P03956       Interstitial collagenase                                MMP1
  Q15788       Nuclear receptor coactivator 1                          NCOA1
  P35228       Nitric oxide synthase, inducible                        NOS2
  P01111       GTPase NRas                                             NRAS
  P11309       Proto-oncogene serine/threonine-protein kinase Pim-1    PIM1
  P61925       cAMP-dependent protein kinase inhibitor alpha           PKIA
  P00749       Urokinase-type plasminogen activator                    PLAU
  P35354       Prostaglandin G/H synthase 2                            PTGS2
  P40763       Signal transducer and activator of transcription 3      STAT3
  P17752       Tryptophan 5-hydroxylase 1                              TPH1
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